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Background: H-rev107, also called HRASLS3 or PLA2G16, is a member of the HREV107 type II tumor suppressor
gene family. Previous studies showed that H-rev107 exhibits phospholipase A/acyltransferase (PLA/AT) activity and
downregulates H-RAS expression. However, the mode of action and the site of inhibition of H-RAS by H-rev107 are
still unknown.
Results: Our results indicate that H-rev107 was co-precipitated with H-RAS and downregulated the levels of activated
RAS (RAS-GTP) and ELK1-mediated transactivation in epidermal growth factor-stimulated and H-RAS-cotransfected
HtTA cervical cancer cells. Furthermore, an acyl-biotin exchange assay demonstrated that H-rev107 reduced H-RAS
palmitoylation. H-rev107 has been shown to be a PLA/AT that is involved in phospholipid metabolism. Treating
cells with the PLA/AT inhibitor arachidonyl trifluoromethyl ketone (AACOCF3) or methyl arachidonyl fluorophosphate
(MAFP) alleviated H-rev107-induced downregulation of the levels of acylated H-RAS. AACOCF3 and MAFP also
increased activated RAS and ELK1-mediated transactivation in H-rev107-expressing HtTA cells following their treatment
with epidermal growth factor. In contrast, treating cells with the acyl-protein thioesterase inhibitor palmostatin B
enhanced H-rev107-mediated downregulation of acylated H-RAS in H-rev107-expressing cells. Palmostatin B had
no effect on H-rev107-induced suppression of RAS-GTP levels or ELK1-mediated transactivation. These results
suggest that H-rev107 decreases H-RAS activity through its PLA/AT activity to modulate H-RAS acylation.
Conclusions: We made the novel observation that H-rev107 decrease in the steady state levels of H-RAS palmitoylation
through the phospholipase A/acyltransferase activity. H-rev107 is likely to suppress activation of the RAS signaling
pathway by reducing the levels of palmitoylated H-RAS, which decreases the levels of GTP-bound H-RAS and also
the activation of downstream molecules. Our study further suggests that the PLA/AT activity of H-rev107 may play
an important role in H-rev107-mediated RAS suppression.
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H-rev107 [1], also called HRASLS3 [2] or PLA2G16 [3],
was first identified in H-RAS-resistant murine fibro-
blasts [4]. H-rev107 is a member of the HREV107 type
II tumor suppressor gene family, which includes H-
REV107, retinoid-inducible gene 1 (RIG1) [5], HRASLS2
[6,7], HRLP5 [8], and HRASLS (A-C1) [9,10], the last of
which is present in humans, rats, and mice. In this family,
the protein contains an NC domain at the N-terminus
and a hydrophobic membrane-anchoring domain at the* Correspondence: afu2215@gmail.com
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unless otherwise stated.C-terminus [11,12]. The proteins in this family exhibit
activities that regulate cellular growth, differentiation,
and apoptosis [13-20].
Some research results provide information about the
molecular mechanisms underlying the biological functions
of HREV107 family proteins. Murine H-rev107, human
H-REV107, and human HRASLS were also shown to
inhibit RAS-mediated transformation of fibroblasts, EC
cells, and tumor cell lines [4,9,21]. Similar inhibition of
RAS signaling pathways has been observed in HRASLS2-
expressing [7] or RIG1-expressing cervical and gastric
cancer cells [13,19,20]. In keratinocytes, RIG1 has been
shown to stimulate cellular differentiation that is mediated
by activating type I tissue transglutaminase or regulatingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tubule ring [15,17,18,22]. HREV107 family proteins also
exhibit proapoptotic activities. The proapoptotic activ-
ities of RIG1 are mediated through caspase-dependent
[14,18,19] or -independent pathways [14,15] in normal
keratinocytes and cancer cells. H-REV107 has been shown
to be a target of interferon-regulatory factor-1 and to be
involved in IFN-γ-induced cell death in human ovarian
carcinoma cells [23].
HREV107 family proteins have recently been considered
phospholipid-metabolizing enzymes. The release of free
fatty acids and lysophospholipid from phosphatidylcholine
catalyzed by H-REV107 indicates that H-REV107 acts
as a phospholipase A [3,24]. Furthermore, phospholipid-
related enzyme activities have also been identified for
RIG1, HRASLS2, A-C1, and HRLP5 [6,8,25]. All members
of this family possess phospholipase A1/2 (PLA1/2) activity
as well as O-acyltransferase activity (i.e., PLA/AT). Although
similar enzyme activities were observed, each member
exhibits a different spectrum of PLA/AT activity. HRASLS2
exhibits higher PLA1/2 activity, whereas O-acylation activity
has been observed in H-REV107 and RIG1 [6].
RAS proteins are plasma membrane associated GTPases.
Different isoforms of RAS (H-, N-, and K-RAS) can regu-
late a variety of cellular processes involving proliferation,
differentiation, and apoptosis. RAS activity is regulated
by guanidine nucleotide exchange factors (GEFs) and
GTPase-activating proteins (GAPs). GEFs activate RAS
by releasing GDP and permitting GTP binding, whereas
GAPs inactivate RAS by catalyzing the hydrolysis of
bound GTP to return RAS to the GDP-bound state
[26-28]. In addition to GTP binding, RAS proteins must
associate with the plasma membrane to transduce their
signals. The CAAX motif of RAS directs the post-
translational modification of the C-terminus of the RAS
protein with a polyisoprenoid lipid [29,30]. This lipid
modification is required for the trafficking of RAS from
the endomembrane system to the plasma membrane
[31]. Palmitoylation (S-acylation) is readily reversible,
and the cycle of depalmitoylation and repalmitoylation
is linked to RAS trafficking to and from the Golgi
apparatus [32-34].
The entire HREV107 protein family can inhibit the RAS
signaling pathway. The exact molecular mechanism by
which H-rev107 inhibits RAS is still unknown. H-rev107
has been shown to possess PLA/AT activity, and the acti-
vation of H- or N-RAS is tightly regulated by its cellular
localization with modification by de- and reacylation. We
hypothesized that H-rev107 may act as a PLA/AT enzyme
to regulate RAS lipid modification and subsequently affect
RAS activity. To discern the role of H-rev107 on RAS pal-
mitoylation, we determined the acylated status of H-RAS
in cells expressing H-rev107. Here we show that H-rev107
can decrease the level of acylated H-RAS. We also showthat H-rev107, via its PLA/AT activity, inhibits the RAS
signaling pathway.
Methods
Expression vectors and materials
The vectors pH-rev107-myc and pH-RAS have been de-
scribed previously [13,35]. The vectors pH-rev107-his
and pH-rev107 (1–132)-his, which encode, respectively,
full-length H-rev107 and H-rev107 with 30 amino acids
truncated at the C-terminus (1–132), were constructed
by amplification from pH-rev107-myc plasmid using




CC-3’ and 5’- GCAAGCTTATCTCTGACCTGATCAC
TCCG-3’). The amplified cDNA fragments were then
subcloned inframe into the BamHI-HindIII sites of the
pET-29a (+) vectors (Novagen, EMD Bioscience, MA,
USA). The cDNA sequences of the fusion proteins were
confirmed by DNA sequencing. Arachidonyl trifluoro-
methyl ketone (AACOCF3) was purchased from Cayman
Chemical (Ann Arbor, MI, USA). Palmostatin B was
purchased from Millipore Corporation (Billerica, MA,
USA). Bromoenol lactone (BEL) and methyl arachidonyl
fluorophosphate (MAFP) were purchased from Sigma
(St. Louis, MO, USA).
Protein expression and purification
Both full length and C-terminal truncated H-rev107 were
isolated and purified from E. coli over-expressing the
respective proteins. Expression of the inserted gene is
via the induction of T7 polymerase with 1 mM isopropyl
β-D-1-thiogalactopyranoside in BL21(DE3) E. coli after
cells reach mid-log phase. Purification of the protein was
facilitated by the polyhistidine tag at the C-terminus of
the H-rev107 fusion proteins. Purified proteins were con-
firmed by Western blot analysis using antibodies against
polyhistidine (Sigma) (data not shown).
Cell culture and transfection
HtTA cervical cancer cells [20] were maintained in RPMI-
1640 medium supplemented with 25 mM HEPES, 26 mM
NaHCO3, 2 mM L-glutamine, penicillin (100 units/mL),
streptomycin (100 μg/mL), and 10% fetal bovine serum
(FBS) at 37°C in an atmosphere of 5% CO2 in air. For
DNA transfection, cells plated in culture dishes were
transfected with the expression vectors using the method
of liposome-mediated transfection. Briefly, plasmids and
lipofectamine 2000 (Gibco BRL, Gaithersburg, MD, USA)
were separately diluted in Opti-MEM medium and then
mixed together and incubated at room temperature for
15 min. The DNA-lipofectamine complexes were then in-
cubated with the cells for 4 h at 37°C. Cells were refreshed
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medium without serum for 12 h. Cells were then stimu-
lated with epidermal growth factor (EGF, 50 ng/mL;
Sigma) for 5 min at 37°C before harvesting. For protein
transfection, cells plated in culture dishes were transfected
with H-rev107(FL) or H-rev107(1–132) using a protein
delivery reagent (PULsin®, Polyplus, BP, France). Protein
was diluted in 20 mM Hepes buffer (pH 7.4) and then
mixed with PULsin® reagent at room temperature for
15 min. The protein-PULsin® reagent complexes were
then incubated with the cells for 4 h at 37°C.
RAS activity assay
RAS activity was assessed using the RAS activation assay
kit (Upstate Biotechnology, Lake Placid, NY, USA). Briefly,
cells in a 10-cm dish were washed twice with ice-cold
phosphate buffered saline (PBS) and then lysed in 0.5 mL
of MLB buffer (25 mM HEPES, pH 7.5, 150 mM NaCl,
1% Igepal CA-630, 10 mM MgCl2, 1 mM EDTA, and
10% glycerol) containing 1× complete protease inhibitor
cocktail (EDTA-free) (Roche Diagnostics, Mannheim,
Germany) and phosphatase inhibitors (2 mM NaF and
1 mM Na3VO4). After centrifugation at 14,000 × g for
5 min, protein in the lysate was quantified using the
Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules,
CA, USA). Cellular lysates containing 300 μg of protein
were then incubated at 4°C for 45 min with 5 μL of RAF-1
RBD agarose bound with glutathione S-transferase fusion
protein corresponding to the human RAS binding domain
(RBD, residues 1–149) of Raf-1. After washing three times
with MLB that contains protease and phosphatase in-
hibitors, the presence of the activated RAS (RAS-GTP)
was detected by Western blotting using an anti-RAS
monoclonal antibody that recognizes RAS (Clone 10,
Upstate Biotechnology).
ELK1 reporter assay
The ELK1 pathway was used to analyze the effects of H-
rev107 on H-RAS induced by EGF using the PathDetect®
in vivo signal transduction pathway transreporting system
(Stratagene, La Jolla, CA, USA). The cells were plated
overnight in triplicate in six-well plates at a density of
2 × 105 cells per well in RPMI-1640 medium that con-
tains 10% FBS. The cells were then cotransfected with
an H-rev107 expression vector or empty control vector,
H-RAS expression vector, the transactivator plasmid
pFA-ELK1, and the reporter plasmid pFR-luc. After
transfection, the cells were incubated for 24 h in medium
that contains 1% FBS and then cultured for 24 h in
serum-free medium containing 10 μM AACOCF3 and
either 1 μM palmostatin B or dimethyl sulfoxide (DMSO)
vehicle (0.1%). To analyze the activity of the transfected
HRAS, the cells were stimulated with EGF (50 ng/mL) for
12 h at 37°C before harvesting. Luciferase activity wasthen measured using the luciferase assay kit (Stratagene)
and a multi-functional microplate reader (Infinite F200,
Tecan, Durham, NC, USA). The relative luciferase activity
of each sample was determined after normalizing the
protein concentration of each lysate. All experiments
were performed in triplicate.
Immunoprecipitation and Western blotting
Cells were lysed in MLB that contains protease and
phosphatase inhibitors. Cell lysates containing 500 μg of
protein were first incubated for 2 h at 4°C with 3.2 μg of
anti-MYC (Invitrogen, Carlsbad, CA, USA) or anti-RAS
(Upstate Biotechnology) monoclonal antibody and then
incubated for 2 h at 4°C with 20 μL of protein G plus/
protein A agarose (Calbiochem, Cambridge, MA, USA).
Immunoprecipitated complexes were analyzed by Western
blotting using an anti-RAS or anti-MYC antibody after
washing three times with PBS. For Western blotting, 20 μg
of protein were separated on 15% polyacrylamide gels
and transferred to polyvinylidene fluoride membranes.
After blocking, membranes were incubated for 12 h at
4°C with anti-MYC, anti-RAS, anti-polyhistidine, or
anti-actin (Sigma) antibody and then incubated with
horseradish peroxidase-conjugated goat anti-mouse anti-
body at room temperature for 1 h. An ECL kit (Amersham,
Bucks, UK) was used to detect the substrate reaction.
The relative protein expression was quantified following
normalization with the levels of the actin.
Acyl-biotin exchange assay
Cells plated in 10-cm dishes were transfected with 5 μg
of expression plasmids and then incubated for 24 h in
complete medium containing 10 μM AACOCF3 and
either 1 μM palmostatin B or DMSO vehicle (0.1%). Cells
were lysed in 1 mL of lysis buffer (50 mM Tris–HCl,
pH 7.2, 1% Triton X-100, 150 mM NaCl, 1% sodium
deoxycholate, 1 mM EDTA, 0.1% SDS, and protease
and phosphatase inhibitors containing 10 mM N-ethyl-
maleimide) (Sigma). Acyl-biotin exchange assays were
performed as described previously with minor modifi-
cations [36]. Briefly, 5 μg of protein were precipitated
using chloroform-methanol and treated exhaustively
with N-ethylmaleimide to block free thiol groups, which
was removed by sequential chloroform-methanol precipita-
tion. The samples were then treated with hydroxylamine
(Sigma) and EZ-Link® HPDP-Biotin (Pierce Biotechnology,
Rockford, IL, USA) to exchange thiol-bound fatty acids
for biotin. Equal amounts of solubilized protein were
incubated with 15 μL of streptavidin agarose resin (Pierce
Biotechnology) at 25°C for 90 min. Immunoprecipitated
complexes were analyzed by Western blotting using an
anti-RAS antibody after washing three times with washing
buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 0.2% Triton X-100, and 0.1% SDS).
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H-rev107 inhibited H-RAS activation induced by EGF
Since H-rev107 was first isolated from revertants of H-
RAS-transformed fibroblasts, we examined the effect of
H-rev107 on the activation of H-RAS. Stimulation of
HtTA cells with EGF significantly enhanced activated
RAS (RAS-GTP) by about 12.3-fold (Figure 1A). The
EGF-stimulated RAS-GTP levels were suppressed in a
dose-dependent manner with maximal 86.6% inhibition
in cells transfected with 3 μg of H-rev107 expression
vector (Figure 1A).
We next examined the effects of H-rev107 on ELK1
transactivation in cells stimulated with EGF for 12 h.
ELK1 transactivation dramatically increased by 7.4-fold
in EGF-treated HtTA cells. We also observed a dose-
dependent downregulation of ELK1 transactivation in
H-rev107-expressing HtTA cells (Figure 1B).
H-rev107 was associated with H-RAS and inhibited its
palmitoylation
The results above suggest that H-rev107 can inhibit H-
RAS activation. We then analyzed whether H-RAS is
the acylated target of H-rev107. We first performed
co-immunoprecipitation with lysates of HtTA cells that
coexpressed H-RAS along with empty vector or H-rev107-
myc fusion protein. Our analysis revealed that H-RAS was
immunoprecipitated along with H-rev107 fusion protein
using anti-MYC antibody against the MYC epitope of the
H-rev107 fusion protein. Similarly, H-rev107 was detected
in the H-RAS immunoprecipitate (Figure 2A).
Palmitoylation or S-acylation is the post-translational
attachment of fatty acids to cysteine residues of RAS.
This modification is essential for the specific subcellular
distribution and the GTP-GDP exchange of RAS [29,30].
H-rev107 has been reported to act as a PLA/AT and to
play a role in the regulation of adipocyte metabolic
processes [3,37]. We then used an acyl-biotin exchangeFigure 1 H-rev107 inhibited activation of H-RAS induced by EGF. (A)
control vector for 24 h and then serum starved for 12 h. Cells were stimula
activated RAS (RAS-GTP) was isolated with RAF-RBD-conjugated agarose. The
Western blotting. (B) HtTA cells were plated in triplicate, incubated overnight
and reporter plasmids, and were then stimulated with EGF (50 ng/mL) for 12
activity of ELK1 protein. Representative results from triplicate samples are expassay to examine the effect of H-rev107 on H-RAS pal-
mitoylation. As shown in Figure 2B, the total amount
of H-RAS in the lysates of H-rev107-expressing cells
did not differ from that in control cell lysates. However,
the amount of H-RAS captured on the biotin-labeled
HPDP was decreased by 50.5% in H-rev107-transfected
lysates treated with hydroxylamine. No acylated H-RAS
protein was detected in the cell lysate in the absence of
hydroxylamine, demonstrating the presence of hydrox-
ylamine-sensitive linkages. This result suggests that
H-rev107 decreases the levels of H-RAS by modifying
lipid acylation of H-RAS.
We next determined the effect of purified H-rev107
protein on RAS palmitoylation. Polyhistidine-tagged H-
rev107 (FL) or H-rev107 (1–132) fusion proteins with the
expected molecular weights of 22.9 and 20 kDa, respect-
ively, were detected in cytosolic extracts prepared and
purified from BL21 (DE3) E. coli cells following induction
by incubation with isopropyl β-D-1-thiogalactopyranoside
for 4 h (Figure 3A). The purity of the full-length and C-
terminal truncated H-rev107 proteins reached 38.2%
and 84.7%, respectively. Similar to results observed in
Figure 2B, the levels of acylated RAS were decreased by
74.7% in HtTA cells transfected with purified H-rev107
(FL) protein compared to the cells transfected with the
control protein R-phycoerythrin (Figure 3B). Although
a higher level of purity was attained for the C-terminal
truncated H-rev107 protein [H-rev107(1–132)], this pro-
tein had no effect on the levels of acyl-RAS in HtTA cells.
PLA/AT inhibitor eliminated H-rev107-mediated inhibition
of H-RAS palmitoylation
Previous studies demonstrated that cycles of de- and
re-acylation can regulate the activity of H-RAS [32,34].
Protein palmitoylation is carried out by palmitoyl acyl-
transferases (PATs) during deacylation by acyl-protein
thioesterases (APTs) [32,38]. We next determined whetherHtTA cells plated in 10-cm dishes were transfected with H-rev107 or
ted with EGF (50 ng/mL) for 5 min. Cell lysates were prepared, and the
levels of total RAS, H-rev107 fusion proteins, and actin were measured by
, transfected for 2 days with control vector, H-rev107 expression vector,
h at 37°C. Cell lysates were prepared and analyzed for the transactivation
ressed as mean ± SD. Student’s t-test: ***, P < 0.001.
Figure 2 H-rev107 was associated with H-RAS and inhibited its palmitoylation. (A) HtTA cells plated in a 10-cm dish were transfected for
24 h with 0.1 μg of H-RAS along with H-rev107-myc or the control vector. Cell lysates were prepared as described in Methods. The interaction
between H-rev107 and RAS was analyzed by immunoprecipitation followed by Western blot analysis. (B) HtTA cells plated in a 10-cm dish were
transfected for 24 h with 0.1 μg of H-RAS along with 3 μg of H-rev107-myc or the control vector. Cell lysates were prepared, and acyl-biotin
exchange analysis of H-RAS was performed as described in Methods. Aliquots containing 5 μg of protein including acylated RAS were biotinylated
and then processed with streptavidin agarose resin followed by Western blot analysis. The input consisted of 300 ng of protein from the acyl-biotin
exchange that was loaded. HC: heavy chain; NH2OH: hydroxylamine.
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thioesterases (APT1) or PLA/AT-induced deacylation/
acylation. We did this analysis by using, respectively, an
APT1 inhibitor (palmostatin B) [39] or a PLA/AT inhibi-
tor (AACOCF3) [3]. We observed that treating HtTA
cells with AACOCF3 slightly increased acylated H-RAS
by 31%. However, acylation of H-RAS was decreased by
47.6% when cells were treated with palmostatin B in
control transfected cells. Treating H-rev107-expressingFigure 3 H-rev107 protein inhibited RAS palmitoylation. (A) Coomassie
from E. coli. The 6 × His-tagged fusion proteins of H-rev107 were purified usin
to 12% SDS-PAGE. (B) HtTA cells plated in a 6-cm dish were transfected for 24
(1–132) protein. Cell lysates were prepared, and acyl-biotin exchange analysis
5 μg of cytosolic extract was collected with streptavidin agarose resin followe
of protein from the acyl-biotin exchange. FL: full length.HtTA cells with AACOCF3 increased acylated H-RAS by
4-fold (Figure 4A), whereas treatment with palmostatin B
decreased the levels of acylated H-RAS by 82.7%.
In order to elucidate the effect of PLA/AT activity
on H-rev107-mediated H-RAS acylation, we performed
a series of studies with commercially available PLA2
inhibitors. AACOCF3 and MAFP have been shown to
inhibit the activity of cytosolic human phospholipase
A2, whereas BEL is a mechanism-based suicide substrateblue staining of purified full-length and C-terminal-truncated H-rev107
g a HiTrap™ Chelating HP column. The purified proteins were subjected
h with 7 μg of H-rev107 (FL) or R-phycoerythrin or 3 μg of H-rev107
of H-RAS was performed as described in Methods. Acylated RAS from
d by analysis by Western blotting. The loading input consisted of 300 ng
Figure 4 AACOCF3 and MAFP eliminated H-rev107-mediated
H-RAS palmitoylation. HtTA cells plated in a 10-cm dish were
transfected for 24 h with 0.1 μg of H-RAS along with H-rev107-myc
or the control vector in the presence of 10 μM AACOCF3 (A, B),
1 μM palmostatin B (A), 5 μM MAFP (B), 2 μM BEL (B) or DMSO
vehicle. Cell lysates were prepared, and acyl-biotin exchange analysis
of H-RAS was performed as described in Methods. Levels of H-RAS
and H-rev107 in the cell lysates are shown in the bottom panel.
NH2OH: hydroxylamine.
Wang et al. Journal of Biomedical Science 2014, 21:36 Page 6 of 9
http://www.jbiomedsci.com/content/21/1/36inhibitor of calcium-independent PLA2. Also, BEL has
been shown to inhibit lipases that contain the GXSXG
consensus motif [40-43]. Expression of H-rev107 resulted
in downregulation of acylated H-RAS by 75.6%. AACOCF3
and MAFP increased acylated H-RAS by 6.4- and 3.8-fold,
respectively, in H-rev107-expressing HtTA cells (Figure 4B).
BEL had no effect on acylated H-RAS production in
H-rev107-expressing HtTA cells.
PLA/AT inhibitor eliminated H-rev107-mediated inhibition
of H-RAS activation induced by EGF
To discern the role of the downregulation of RAS activation
in H-rev107-mediated lipid modification, we determined
whether H-rev107-mediated suppression of RAS-GTP
was relieved by the PLA/AT inhibitor AACOCF3. EGF
increased RAS-GTP levels by 5.4-fold in HtTA cells. The
EGF-stimulated RAS-GTP level in H-rev107-expressing
HtTA cells was inhibited by 36% compared to controltransfected cells (Figure 5A). This suppression was absent
in cells treated with AACOCF3. In contrast, AACOCF3
by itself had no effect on the level of RAS-GTP in control
cells. Palmostatin B had no effect on the levels of RAS-
GTP in either control or H-rev107-expressing HtTA cells
(Figure 5A).
We further determined the effect of APT1 or PLA/AT
inhibitors on ELK1 transactivation in response to EGF
stimulation. In control cells, EGF treatment for 12 h
significantly increased ELK1 transactivation. The effect
was not altered by co-incubation with AACOCF3 or
palmostatin B (Figure 5B). However, EGF-stimulated
ELK1 transactivation in H-rev107-expressing cells was
decreased by 74%, and the inhibition was alleviated by
AACOCF3, but not by palmostatin B (Figure 5B).
Therefore, AACOCF3 eliminated H-rev107-mediated
suppression of acylated H-RAS. Also, treating cells with
AACOCF3 significantly restored H-rev107-mediated
suppression of H-RAS-GTP and ELK1 transactivation.
In addition, we also determined the effect of PLA2
inhibitors on H-rev107-mediated H-RAS activation. As
shown in Figure 5C and D, treating H-rev107-expressing
HtTA cells with AACOCF3 and MAFP increased H-
RAS-GTP levels and restored H-RAS-mediated ELK1
transactivation.
Discussion
The HREV107 protein family has been shown to nega-
tively regulate the activity of RAS [4,7,13,19,20]. Most
studies have emphasized the regulation of the down-
stream signal of RAS by HREV107 protein. Our previous
studies indicated that RIG1 or HRASLS2 suppresses
RAS-GTP formation [7,13]. Palmitoylation is essential
for the trafficking of H-RAS and N-RAS to the plasma
membrane. The current study has shown that H-rev107
downregulates H-RAS lipid acylation. This lipid regulation
by H-rev107 on RAS may affect subcellular localization
and also the RAS activation upon EGF treatment. The
results support our previous observation of enhanced
Golgi-localized H-RAS in RIG1-transfected cells [13].
Several recent studies demonstrate that each member of
the HREV107 protein family may act as a phospholipid-
related enzyme to catalyze the release of fatty acid from
glycerophospholipid or the transfer of an acyl group
from glycerophospholipid to the hydroxyl group of lyso-
phospholipid [6,8,24,25,37]. The acyltransferase activity
of HREV107 was mainly focused on N-acylation and O-
acylation activities for HRASLS2, H-REV107, and RIG1
[6,37]. Whether the HREV107 protein family can regulate
palmitoylation or S-acylation had not been investigated.
Our results show that H-rev107 can decrease acylated H-
RAS. This observation suggests that H-rev107 possesses
S-acyltransferase activity and that H-RAS may be the
donor for thioester transfer catalyzed by H-rev107. We
Figure 5 AACOCF3 and MAFP eliminated H-rev107 inhibition of H-RAS activation induced by EGF. (A, C) HtTA cells plated in 10-cm dishes
were transfected for 24 h with H-rev107 or control vector in the presence of 10 μM AACOCF3, 5 μM MAFP, 2 μM BEL, 1 μM palmostatin B or
DMSO vehicle. Cells were then serum starved for 12 h and stimulated with EGF (50 ng/mL) for 5 min. Cell lysates were prepared, and activated
RAS (RAS-GTP) was collected with RAF-RBD-conjugated agarose. The levels of total RAS, H-rev107 fusion proteins, and actin were measured by
Western blotting. (B, D) HtTA cells were plated in triplicate, incubated overnight, and then transfected for 2 days with control vector, H-rev107
expression vector, and reporter plasmids in the presence of 10 μM AACOCF3, 1 μM palmostatin B, 5 μM MAFP, 2 μM BEL, or DMSO vehicle. Cells
were starved and then stimulated with EGF (50 ng/mL) for 12 h at 37°C. Cell lysates were prepared and analyzed for the transactivation activity of
ELK1 protein. Representative results from triplicate samples are expressed as mean ± SD. Student’s t-test: **, P < 0.01; ***, P < 0.001.
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deacylated H-RAS from acylated H-RAS. Acyl-H-rev107
intermediate would be then be hydrolyzed to release
fatty acid or to transfer the S-acyl group to other cysteine
residues of proteins such as Gsα or β2-adrenergic receptor.
The acceptors for the S-acyltransferase activity of H-rev107
need to be identified.
H-rev107 activity that suppressed H-RAS acylation is
eliminated by AACOCF3 and MAFP, but not by BEL.
The inhibitory effect of AACOCF3 and MAFP on H-
rev107 is similar to a previous study [3]. The results
indicate that PLA/AT activity of H-rev107 is required
for both phospholipase activity and the regulation of H-
RAS acylation. In contrast, decreasing the deacylated
reaction using APT1 inhibitor did not restore the acyl-
ated H-RAS level in control or H-rev107-expressing
cells. Palmostatin B has been shown to inhibit APT1
activity and perturb the cellular acylation cycle of RAS
for a short time [39,44]. The acylation/deacylation cycle
of RAS is perturbed by plamostatin B, and this may result
in de novo synthesis of RAS and long-term feedback
suppression of RAS activity. Furthermore, palmostatin
B might suppress RAS activity regardless of its ability
to inhibit the deacylation enzyme APT1 [45]. Comparisonof the effect of PLA inhibitors and APT1 inhibitor on
H-rev107-mediated RAS suppression suggests that the
steady-state level of H-RAS within cells, as regulated by
H-rev107, can be controlled by PLA, but not by APT1.
Treating cells with AACOCF3 and MAFP resulted in
more acylated H-RAS production compared to control
cells. Increases in RAS-GTP protein were not observed
in cells treated with these inhibitors. Activation of RAS
proteins is tightly regulated by GEFs, which exchange
GDP for GTP to produce an active, GTP-bound state.
GAPs can also catalyze the hydrolysis of bound GTP to
turn off RAS [29]. The location for the GDP-GTP cycle
for RAS processing is at the plasma membrane, and this
subcellular localization is controlled by RAS lipid modi-
fication. As shown by the RAS activity assay, AACOCF3
and MAFP may cause more RAS trafficking to the
plasma membrane, but these inhibitors had no effect on
GEF/GAP activity.
Examination of the enzyme activity of the HREV107
protein family may help to clarify its biological activity.
In this study, we demonstrated that the anti-RAS activity
of H-rev107 may result from the latter’s PLA/AT activity.
Our previous studies also showed that H-rev107 and
RIG1 can regulate PGDS activity, which enhances PGD2
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has been shown to be required for the activity of
phospholipase A [47,48]. Whether H-rev107-mediated
regulation of PGDS activity is controlled by the PLA/
AT activity of H-rev107 requires further investigation.
Posttranslational lipid modification has diverse effects
on cellular signaling. Therefore, pleiotropic effects of
HREV107 family proteins in the regulation of cellular
growth, differentiation, and apoptosis may be intimately
associated with their lipid-metabolizing abilities.
There is little literature comparing the effects of each
member of the HREV107 family on physiology. H-rev107,
HRASLS2, and RIG1, each of which contains a highly
conserved NC domain, exert similar biological effects with
regard to anti-RAS and proapoptotic activity [5,7,14,20].
Although diverse C-terminal transmembrane domains are
present in each member of the HREV107 family, all family
members localize to similar organelles within cells, such
as the endoplasmic reticulum or Golgi apparatus [7,9,19].
Nazarenko et al. showed that H-rev107 in the nucleus
stimulates the growth of non-small cell lung carcinoma
[49]. Similarly, proapoptotic activity was observed with
cells that expressed full-length or truncated RIG1 that
appeared in the perinuclear region or nucleus, respectively
[14]. In addition to cellular function, tissue distribution
should also be considered. H-rev107 and RIG1 were
shown to be expressed similarly except in peripheral
leukocytes, whereas HRASLS2 is expressed only in liver,
kidney, testis, intestine, and colon [6]. The different
expression profiles of the HREV107 family in humans
might reflect tissue-specific activity or the redundancy
of gene evolution.
The relation of the phospholipid-metabolizing activity
of the HREV107 protein family to its anti-tumor activity
remains unclear. Here we provide insight into the
phospholipid-metabolizing activity of H-rev107, which
regulates RAS palmitoylation and thereby affects RAS
activity. Metabolites produced by HREV107 protein
and/or the enzyme activity itself are likely to play roles
in inducing cellular differentiation and suppressing
cellular growth. Analysis of PLA/AT activity of the
HREV107 family proteins in other known processes,
such as proapoptosis [5,7,14] or transglutaminase [15,22]
or in target molecules such as PGDS [35,46] would help
elucidate the mechanism responsible for the biological
functions of the H-REV107 family proteins.
Conclusions
Our study revealed that H-rev107 exerts its anti-RAS
activity through its PLA/AT activity to decrease the
steady state levels of H-RAS palmitoylation. Suppression
of PLA/AT activity alleviates the H-rev107-mediated
suppression of RAS activity, which to our knowledge
has not been investigated previously.Abbreviations
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